

Under the Paperwork Reduction Act of 1994, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.: 2001_1248A

First Named Inventor : Teruaki SEKINE et al.

Title: METHOD AND ACTIVATED LYMPHOCYTE PREPARATIONS
FOR PREVENTING RECURRENCE OF CARCINOMA

Express Mail Label No.:

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. ☒ Small Entity Status is hereby asserted.
3. ☒ Specification [Total Pages: 13]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Sequence Listing, a table, or a computer program listing appendix.
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☐ Drawing(s) (35 USC 113) [Total Sheets:]
5. ☒ Oath or Declaration [Total Pages : 2]
 - a.1. ☐ Newly executed (original or copy)
 - a.2. ☒ Unexecuted
 - b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
 - i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named
in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet (see 37 CFR 1.76)

7. ☐ CD-ROM or CD-R in duplicate, large table or computer program (Appendix)
8. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☐ Computer Readable Form
 - b. Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☐ Paper
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement (when there is an assignee)
 - ☐ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449
 - ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i).
Applicant must attach form PTO/SB/35 or its equivalent.
17. ☒ Other Cover Letter

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below, and in a preliminary amendment, or in an Application Data Sheet :

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.

Prior Application Information: Examiner

Group Art Unit

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference therein. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS



000513

PATENT TRADEMARK OFFICE

By:

 Warren M. Cheek, Jr.
 Registration No. 33,367

 WENDEROTH, LIND & PONACK, L.L.P.
 2033 "K" Street, N.W., Suite 800
 Washington, D.C. 20006-1021
 Phone: (202) 721-8200
 Fax: (202) 721-8250

September 4, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Teruaki SEKINE et al. :
Serial No. NEW : Attn: APPLICATION BRANCH
Filed September 4, 2001 : Attorney Docket No. 2001_1248A

METHOD AND ACTIVATED LYMPHOCYTE
PREPARATIONS FOR PREVENTING RECURRENCE
OF CARCINOMA

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975.

PATENT OFFICE FEE TRANSMITTAL FORM

Assistant Commissioner for Patents,
Washington, DC 20231

Sir:

Attached hereto is a check in the amount of \$355.00 to cover Patent Office fees relating to filing the following attached papers:

New application \$355.00
Additional Claims Fee:
Excess of Twenty \$
Independent \$
Multiple Dependent Fee \$

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

Respectfully submitted,

Teruaki SEKINE et al.

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
WENDEROTH, LIND & PONACK, L.L.P.
2033 K St., N.W., Suite 800
Washington, D.C. 20006-1021
Telephone (202) 721-8200
September 4, 2001

[Check No. 46271]

2001_1248A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Teruaki SEKINE et al. : Attn: APPLICATION BRANCH
Serial No. NEW : Docket No. 2001_1248A

Filed September 4, 2001 :

METHOD AND ACTIVATED LYMPHOCYTE
PREPARATIONS FOR PREVENTING RECURRENCE
OF CARCINOMA

**THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975.**

**COVER LETTER ACCOMPANYING APPLICATION FILED WITHOUT EXECUTED
DECLARATION UNDER 37 CFR 1.53(b) AND IN A LANGUAGE
OTHER THAN ENGLISH UNDER 37 CFR 1.52(d)**

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Enclosed is a new patent application entitled "METHOD AND ACTIVATED
LYMPHOCYTE PREPARATIONS FOR PREVENTING RECURRENCE OF CARCINOMA".
This application is submitted in the Japanese language under the provisions of 37 CFR 1.52(d).

Furthermore, the present application is submitted under the provisions of 37 CFR 1.53(b),
and the application as filed does not include an executed declaration. However, accompanying
the application is an unexecuted declaration listing the inventor information.

The application as filed further does not include an executed power of attorney, and
accordingly, it is requested that communication initially be directed to the following firm, until an
executed power of attorney and declaration are filed:

WENDEROTH, LIND & PONACK, L.L.P.
2033 K Street, N.W., Suite 800
Washington, D.C. 20006-1021

Telephone: (202) 721-8200
Facsimile: (202) 721-8250

20010904

The required filing fee of \$355.00 is enclosed.

Respectfully submitted,

Teruaki SEKINE et al.

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
September 4, 2001

20060904 09:46:00